The European Commission for the Control of Foot-and-Mouth Disease (EuFMD)

Research Group of the Standing Technical Committee 'Open Session' 2016

26/10/2016 - 28/10/2016
Cascais, Portugal,


Day 1 – PLENARY 

1.1 Opening: Global Situation (Frenkel lecture)

1.1.a EuFMD: Opening (available video presentation)

1.1.b Frenkel Lecture (A. Dekker)   

1.1.c Update on Current Global Situation for FMD: New Outbreak and Threats (D. King) 


1.2 The livestock sector and disease emergencies: Innovation and Ideas

1.2.a Change in the Management of FMD Disease Control to a Private-Public-Partnership (V. Shütz)   

1.2.b A ‘Readiness Rating’ for Balancing Biosecurity Priorities in FMD Preparedness and Response (R. Horwitz)   

1.2.c Organisation of Raw Milk Collection during a FMD Outbreak (Y. Templeman)   

1.2.d Economic Costs and Effects of Activities to Prevent FMD in Denmark (S. Mortensen)   

1.2.e Cost and Responsibility Sharing Arrangements in the EU to Prevent and Control Notifiable Veterinary Risks (R. H.M. Bergevoet) 


1.3 Higher health compartments: The way ahead?

1.3.a Non-Geographical Approaches to FMD Risk Management Forum (G. Thomson)   

1.3.b Advancements in Compartmentalisation and Regionalisation-Opportunities, Relationships, Information and Challenges Forum (E. Parker)   

1.3.c Capability Analysis and Scenarios of Resources Pooling in case of FMD Epizootics in France and Tunisia Forum (M. Marsot)   

1.3.d Spread of FMD Serotype O-PANASIA2 in a Dairy Complex in Iran (C. Bartels)   

1.3.e A Risk-Based Model to Guide Decisions on Zonification to Stop Vaccination in a Free Country with Vaccination (J. L. Gonzales)   


1.4 Vaccination as an option: What challenges remain?

1.4.a Encouraging the Use of Vaccination-To-Live as a Control Strategy for FMD Outbreaks (K. De Clercq)   

1.4.b Improving Access to Emergency FMD Vaccine Through A Vaccine Bank Sharing Arrangement (T. Smylie)   

1.4.c Which Vaccines are Most Important? A Decision Support Tool for Foot and Mouth Disease Vaccine Bank Manager (M. McLaws)   

1.4.d Early Decision Indicators to Predict the Severity of an FMD Outbreak (C.Cook)   

1.4.e Emergency Vaccination Benefits Eradication of Hypothetical Introductions of FMD into New Zealand (Z. Yu)   

1.4.f A Process Modelling Approach to Estimate FMD Diagnostic Capacity for Outbreak Management Decision-Making (K. Walker)   

1.4.g Quantifying the Value of Perfect Information in Emergency Vaccination Campaigns for FMD (M. Tildesley)   




2.P1 Global Progress against FMD: Session organised by the FMD working group of FAO and OIE

2.P1.a Global, Regional and National Progress of FMD Control (S. Metwally)

2.P1.b FMD Disease Risk Assessment and Progress on Risk-Based Control Program (A. Bulut)

2.P1.c National Activities for FMD Control in Afghanistan (G. Ferrari)


2.P2 Vaccine Efficacy (GFRA )

2.P2.a Advances and Gaps in Vaccine Modelling (R. Reeve)

2.P2.b Selection of FMD Vaccines in Vietnam (D. Do Huu)   

2.P2.c The Value of In Vitro Antigen Matching in Predicting Vaccine Protection (W. Vosloo) 

2.P2.d Correlation of Serological Response After Vaccination Against FMDV and Protection Against Challenge in Pigs (P. L. Éble)   

2.P2.e Novel Marker FMD Virus Vaccine Molecularly Bound to Nanolipoprotein Adjuvant (E. Rieder)   

2.P2.f Antigenic Refocusing of A SAT2 FMD Virus Through Epitope Dampening (T. Ramulongo)

2.P2.g Estimate of Cross-Protection Provided by an FMDV O-BFS Vaccine in the Tunisian Epidemiological Context (E. Brocchi)   


2.P3 FMD Endemicity (GFRA)

2.P3.a The Role of Asymptomatic Carriers in FMD Ecology; Unifying Knowledge from Controlled Laboratory Experiments and Filed Studies (J. Arzt)   

2.P3.b Next Generation Sequencing Reveals New Southern African Territories Genotypes Bringing Us Closer to Understanding the History of FMD Virus in Africa (N. Knowles)   

2.P3.c Waves of FMD in East Africa and Advances in Practical Surveillance (T. Lembo)   

2.P3.d Genetic and Antigenic Variation of FMD Virus During Persistence in Naturally Infected Cattle and Buffalo (J. K. Biswal)   

2.P3.e Molecular Epidemiology of Foot-and-Mouth Disease Viruses in Southern Africa (C. Kasanga)   

2.P3.f A Novel Approach for Endemic FMD in Sub-Saharan Africa (M. Bronsvoort)   




3.1 Global and regional FMD surveillance

3.1.a The Origin, Evolution and Diagnosis of Seneca Valley Virus, A New Vesicular Disease-Causing Picornavirus of Pigs (N. Knowles)   

3.1.b Outbreaks of Foot-and-Mouth Disease Virus in the Middle East During 2015 and 2016 Due to an Exotic A/ASIA/G-VII(G18) Lineage (J. Wadsworth) 

3.1.c Full Genome Study on the Evolution of the FMD Virus O/ME-SA/IND-2001d Lineage: Evidence of Recombination (K. Bachanek-Bankowska) (available video presentation)

3.1.d Genetic Characterization of FMD Viruses in Balochistan, Pakistan (S. M.Jamal)   

3.1.e The Epidemiological Trend of FMDV in Pakistan: A Step Forward to Future Planning to Control FMD in Pakistan (U. Waheed)   

3.1.f Genetic characterization of the 2016 FMD Viruses in South Korea (B. K. Ku)   

3.1.g Current State of FMD Surveillance in Senegal (M. Moustapha)   

3.1.h Genetic Characterization of FMD Virus Isolated During Cross-Sectional Surveillance Studies in Cattle from Uganda During 2014-2015 (Z. Ahmed)   

3.1.i Epidemiology of FMD in Georgia (Z. Rukhadze)

3.1.l Antigenic and Genetic Characterization of FMD Virus Serotype O Circulation in South-East Asia (S. Upadhyaya, M. Mahapatra) 


3.2 New insights from epidemiology studies

3.2.a Detection and Molecular characterization of FMD Viruses from Outbreaks in Northern Nigeria 2013-2015 (A. De Vleeschauwer)   

3.2.b Antigenic and Evolutionary Analysis of FMD Viruses from the 2014-2015 Outbreaks in the Maghreb Region (G. Pezzoni)   

3.2.c Sero-Epidemiological Study of FMD in Livestock in West Libya (A. S. Dayhum)   

3.2.d Epidemiological Parameters from Transmission Experiments: New Methods for Old Data (S. Gubbins)   

3.2.e Complete Genome Sequences of Three African FMD Viruses form Clinical Samples Isolated in 2009 and 2010 (K.De Clercq)   

3.2.f Surveillance of FMD in Georgia (M. Donduashvili)   

3.2.g The Role of Seasonal Movement of Animals in FMD Control in Azerbaijan (T. Aliyeva)

3.2.h Horizontal Transmissibility of the FMD Virus O/JPN/2010 Among Different Species of Animals (K. Fukai)   

3.2.i Molecular Epidemiology of FMD Sudanese Isolates in 2012 (I. Habiballa)   


3.3 Risk based approaches: What have we learnt?

3.3.a Prioritisation of Resources for Early Detection of Disease Incursions (A. Cameron)   

3.3.b Predicted Improved Control of FMD Transmission Between Farms by Using Preclinical Detection (N. Nelson)   

3.3.c Defining the Spatio-Temporal Scale of FMD Virus Lineages Emergence in the Middle East Region (A. Di Nardo)   

3.3.d Transboundary High Risk Area Coordinated Epidemio-Surveillance Programe (THRACE) in Bulgaria, Greece and Turkey (E. Klement)   

3.3.e First Report of FMD Virus (FMDV) Serotypes O Isolation in Puppies in Iran (D. Abdollahi)


3.4 Measuring impact of vaccination and other preventive measures

3.4.a FMD Vaccination and Post-Vaccination Monitoring in Afghanistan: Issues and Challenges (G. Ferrari)   

3.4.b Country Specific Vaccine Can Effectively Control FMD in Endemic Settings (M. Afzal)   

3.4.c Evaluation of Routine Vaccination Against FMDV Serotype A Lineage G-VII on Large Scale Dairy Farms in Saudi Arabia (N. Lyons)   

3.4.d The Serological Response Induced by Inactivated FMD Vaccine in Israel-Clinical Trials in a Dairy Farm (E. Klement)   

3.4.e Farmers’ Intention and Perceptions That Influence Them in Implementing Foot and Mouth Disease Control in Ethiopia (W. T. Jemberu)   

3.4.f The Current Epidemiology and the Control Strategy of FMD in China (Y. Li) (available video presentation)

3.4.g Epidemiology of FMD in Vaccinated Dairy Herds: Transmission Dynamics and the Persistence of the Carrier State (K. VanderWaal)   

3.4.h Assessment of FMD Spread Dynamics in Anatolia of Turkey- Serosurveillance conducted in 2014-15 (A. Bulut)   




4.P1 New Vaccines

4.P1.a A Prime-Boost Vaccination Strategy in Cattle to Prevent Serotype O FMDV Infection Using A “Single-Cycle” Alphavirus Vector and Empty Capsid Particles (G. J. Belsham)   

4.P1.b Vaccine Efficacy of FMD Virus-Like Particles Produced by the Baculovirus Expression System (E. van den Born) 

4.P1.c Enhanced Potency and Immunogenicity for Cattle Vaccinated with FMD A Serotype Vaccine Adjuvanted with Poly (I:C) (S. Parida)   

4.P1.d Effect of the Antigen Payload, Polyvalency and Re-Vaccination in the Protection Conferred by FMD Vaccines Against Heterologous Challenge in Cattle (M. Pérez-Filgueira)   

4.P1.e Immune Responses to Foot-and-Mouth Disease Virus in Guinea Pigs After Vaccination with Canine Adenovirus Vector (S. Lacour)   

4.P1.f EU Authorisation of Novel Vaccines (M. Ilott)   


4.P2 Improving current vaccines

4.P2.a Application of Indirect and Avidity ELISA Tests to Assess Anti-FMDV Antibodies Induced by Vaccination in Buffalo and Swine Serum Samples (A. Capozzo)   

4.P2.b Demonstration of Early Protection Against FMD Virus Seven Days Post-Vaccination (L. Curet) (available    video presentation)

4.P2.c Efficacy of a FMD Inactivated Vaccine (Aftovaxpur DOE), Administered at a 1ml Dose to Sheep (C. Hamers)   

4.P2.d No Heterologous Protection with FMD SAT2 SAU Vaccine Against SAT2 BOT Challenge (A. Dekker)   

4.P2.e Selection of an Adjuvant to Raise Polyclonal Antibodies to FMDV in Rabbits and Guinea-Pigs (B. Sanz-Bernardo)   

4.P2.f Application of A Mouse Model for Effective Evaluation of FMD Vaccine (J.H. Park)   

4.P2.g Development of a Virulent FMD Challenge Model in Sheep (L. Mouton) (available video presentation)


4.P3 Preventing FMD: tools to assist decision making

4.P3.a FMD in Turkey- Livestock Movements and Mathematical Modelling (P. Dawson)   

4.P3.c The U.S. Animal Movement Model (USAMM), A Bayesian Approach to Modeling of a Partially Observed Continental Scale Livestock Movement Network (P. Brommesson)   

4.P3.d Real-Time Bayesian Data Assimilation and Prediction for Livestock Epidemics (C. Jewell)

4.P3.e Real-Time Updating in Emergency Response to FMD Outbreaks (W. Probert)   

4.P3.f Haebos, A Hybrid Agent-and Equation-Based Model of FMD in Vermont (A. Yoak)   

4.P3.g Reducing Computing Times of Spatially Explicit FMD Models (S. Sellman)   


4.P4 Innovation in diagnosis

4.P4.a Development of Novel Virus Neutralization Assay Using QRT-PCR-Based Endpoint Assessment for Rapid Detection and Titration of Neutralising Antibodies Against FMD Virus (Z. Zhang)   

4.P4.b Competitive Luminex Immunoassays for the Detection of Antibodies to FMD and Vesicular Stomatitis Viruses in Multiple Susceptible Hosts (C. K. Nfon)   

4.P4.c Tailed Primers Enhance Real-Time RT-PCR Detection of FMD Virus (D. Lefebvre)  

4.P4.d Development of One-Step Multiplex RT-PCR Assay for Differentiation of FMDV Serotypes A, O and SAT2 Circulating in Egypt (A.A. Shehata)   

4.P4.e Go Prime: In Silico Testing of rRT-PCR Primers and Probes for Diagnosis of FMD (E. Howson)   

4.P4.f Development of a Reference FMD Virus Antigen Panel for the Consistent Validation of Diagnostic Assays (A. Morris)   

4.P4.g Establishment and Validation of Two Duplex One-Step Real-Time RT-PCR Assays for Diagnosis of FMD (L. Bakkali-Kassimi)   

4.P4.h Evaluation of Alternative Cell Lines for the Isolation of FMDV (A. Gray)   

4.P4.i Comparison of Two Commercial NSP Antibody Tests (PRIOCHECK® AND IDVET® FMDV NS ELISAS) to Detect Infection in Vaccinated Animals (DIVA) (S. Parida)   

4.P4.l Detection of FMD Virus Carrier Cattle: Development and Evaluation of an IGA ELISA Kit for O, A and Asia 1 Serotypes (K. Parekh)   

4.P4.m The Challenges of Using in-Vitro Tests for Vaccine Matching (A. Bin-Tarif)   




5.1 Innovations in Training and Knowledge Exchange

5.1.a ‘’www.Training” The Who, What and Where of Building Capacity for FMD Control in The Information Age (J. Maud)  

5.1.b Training for Change or Changing the Training (C. Bartels)   


5.2 Globalising Access to Knowledge and Innovation

5.2.a UK Experience of Modelling in Support of FMD Control, Applying New Approaches to Knowledge Transfer, and Tackling the Challenge of Maintaining and Making Best Use of Global Funding in Support of Research and Innovation (N. Gibbens)   




6.G4 Innovative Surveillance Options for Field Use

6.G4.a Evaluation of Oral Swabs for FMDV Surveillance (P. Kirkland)   

6.G4.b Use of Lateral Flow Device For Safe and Low Cost Shipment of FMDV Suspected Samples (S. Blaise-Boisseau)  

6.G4.c Development of a Successful Surveillance Model for FMD in Pakistan (M. Hussain)   

6.G4.d Progress to Develop Practical Field-Based Tools for Detection of FMD VirusForum (V. Fowler)   


6.G5 Diagnostics: Harmonisation of Laboratory Tests, and Tools to Share Sequence

6.G5.a Results of the 2015 Proficiency Testing Scheme (A. Ludi)   

6.G5.b Vibasys and FMDV-Tools: Practical Resources for FMD Virus Sequence Analysis (P. Ribeca) (available video presentation)

6.G5.c Antigen-Detection ELISA Performance VS Virus Evolution (V. Mioulet)   

6.G5.d Do Commercially Available Lysis Buffers Inactivate FMD Virus? (B. Wood) 


6.G6 Biocontainment of FMDV: Challenges and Solutions for Laboratory Biorisk Management

6.G6.a A Contaminated Environment is an Efficient Route of Transmission for FMD Virus (C. Colenutt)   

6.G6.b Evaluating the Survival of FMD Virus in The Environment (E. Brown)   

6.G6.c The New Zealand National Biocontainment Laboratory Project - Innovative Approaches to meet Testing Requirements in the Event of an FMD Outbreak (R. P.Spence)   

6.G6.d EU FMDV Biorisk Management Committee (K. Summermatter)   


6.G10 New Developments in Wildlife (FMDV in African Buffalo)

6.G10.a Serological and Molecular Surveillance of FMDV Transmission Events Over Time in an Isolated African Buffalo Herd in the Kruger National Park (K. Scott)   

6.G10.b FMD in African Buffalo (Syncerus Caffer): Differences in Host Responses Between SAT1, 2 and 3 in Experimental and Natural Infection (B. Beechler)   

6.G10.c Specificity of FMD Surveillance in Wild Boars (Y. Ivanov)   

6.G10.d Wildlife Surveillance and Control for Foot-and-Mouth Disease (T. Alexandrov)


6.G11 Pathology and Pathological Basis of Persistence

6.G11.a Pathological Change of the Development of the Vesicular Lesion in Pigs Experimentally Infected With the FMD Virus O/JPN/2010 (M. Yamada)  

6.G11.b FMDV-Host Interaction in a Model of Persistenly Infected Bovine Cells (S. Blaise-Boisseau)

6.G11.c Localization of FMD RNA and Viral Antigens in Different Tissues From Apparently Healthy Cattle and Buffalo Under Natural Condition in India: Pathology and Pathological Basis of Persistence (R. Ranjan)   


6.G12 Funding Innovation: Q&A

6.G12.a Funding and Innovation Q&A (available video presentation)